immatics’ financial basis is solid, with leading international life science investors endorsing its business.
With its series A financing round in 2004/2005, immatics has raised more than € 14 million from top tier venture capital firms.
In February 2007, in addition to the existing consortium, Dietmar Hopp as the new lead investor together with new co-investors, committed additional € 40 million to support the success story of immatics. This marks the closing of the largest private biotech financing round in Germany since the year 2001.
INVESTORS
3i Group
-/ www.3i.com
Dievini Hopp BioTech Holding GmbH & Co.KG
EMBL Ventures
-/ www.embl-ventures.com
Grazia Equity
-/ www.grazia-equity.com
KfW Anstalt des öffentlichen Rechts
-/ www.kfw.de
L-EA
-/ www.l-ea.de
Merifin Capital
-/ www.merifin.com
National Technology Enterprises Company
-/ www.ntec.com.kw
Seed
-/ www.seed-gmbh.de
Vinci Capital/Renaissance
-/ www.vincicapital.ch
-/ www.renaissance-pme.ch
Wellington Partners
-/ www.wellington-partners.com














































